ESR1 and breast cancer: The introduction in clinical practice of CDK4/6 inhibitors, which inhibit cyclin D1 pathways and arrest the proliferation of ER-positive BC cells, in combination with estrogen therapy or an LHRH agonist, had a minor impact on intracranial disease control in BM [180,181,182], but the activity in LM has not been investigated thus far.